Clinical trials: Retinal Vein Occlusions
Branch Retinal Vein Occlusion
Combined Therapy of Posterior Subtenon Triamcinolone Acetonide and Intravitreal Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion
This study compares the efficacy of intravitreal bevacizumab monotherapy only or combined therapy of posterior subtenon's triamcinolone acetonide and intravitreal bevacizumab for the treatment of macular edema associated with…
- Trial name
- NCT01614509
- Testing
- intravitreal bevacizumab monotherapy, combined therapy of posterior subtenon triamcinolone acetonide and intravitreal bevacizumab injection
- Where
- South Korea
- Volunteers
- 45 people
- Sponsor
- Yeungnam University College of Medicine
Retinal Vein Occlusion
To Study the Effectiveness and Safety of Niacin and a Topical Steroid Eye Drop to Treat Retinal Vein Occlusions
The purpose of this study is to determine whether Niacin, a B vitamin, may act as a vasodilator to encourage earlier formation of collateral blood vessels that may serve to bypass the obstructed vein in the eye.
- Trial name
- NCT00493064
- Testing
- Nicotinic acid, Prednisolone acetate
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Palo Alto Medical Foundation
Retinal Vein Occlusion
Ozurdex for Retinal Vein Occlusion Study (ORVO Study)
To measure the pro-permeability factors in the aqueous humor of patients with persistent/recurrent macular edema after an injection of Ozurdex.
- Trial name
- ORVO (NCT01790685)
- Testing
- dexamethasone implant
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Johns Hopkins University
Retinal Vein Occlusion, Macular Oedema
Retrospective Data Collection Study in Patients Receiving Two or More OZURDEX® Injections for Macular Oedema Secondary to Retinal Vein Occlusion
The purpose of this study is to use retrospective data to evaluate the efficacy, safety and re-injection interval of OZURDEX® in the treatment of macular oedema due to retinal vein occlusion (RVO) in patients who received…
- Trial name
- NCT01566526
- Testing
- dexamethasone intravitreal implant 0.7 mg
- Where
- Belgium
- Volunteers
- 26 people
- Sponsor
- Allergan
Macular Edema, Retinal Vein Occlusion
Study of Ozurdex® Treatment Practice in Patients With Macular Oedema Due to Retinal Vein Occlusion
Epidemiological study of Ozurdex® in sites treating patients with retinal vein occlusion.
- Trial name
- NCT01618266
- Testing
- dexamethasone intravitreal implant
- Where
- France
- Volunteers
- 375 people
- Sponsor
- Allergan
Retinal Vein Occlusion, Macular Edema
Safety and Efficacy Study of Ozurdex® Compared to Lucentis® in Patients With Branch Retinal Vein Occlusion
This study will evaluate the safety and efficacy of dexamethasone intravitreal implant (Ozurdex®) compared to ranibizumab (Lucentis®) in patients with branch retinal vein occlusion (BRVO).
- Trial name
- NCT01427751
- Testing
- dexamethasone intravitreal implant, ranibizumab
- Where
- 6 sites in France, Germany and 4 more
- Volunteers
- 307 people
- Sponsor
- Allergan
Macular Edema, Branch Retinal Vein Occlusion
REtinal Vein OccLUsion Treatment With Scatter Laser Guided by UWFA in combiNAtion With Ranibizumab Study
Branch retinal vein occlusion is a leading cause of vision loss. Treatment with ranibizumab (vascular endothelial growth factor (VEGF) inhibitor) on a monthly basis has been associated with improved vision results.
- Trial name
- Revolution (NCT01247220)
- Testing
- Ranibizumab, Peripheral Laser
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Retina Associates of Florida, P.A.
Retinal Vein Occlusion, Macular Edema
Retrospective Study in Patients Receiving Two or More OZURDEX® Injections for Retinal Vein Occlusion (RVO)
This is a retrospective data collection study to evaluate the efficacy, safety, and re-injection interval of OZURDEX® in the treatment of macular edema due to RVO. Following informed consent, there were no patient study visits.
- Trial name
- NCT01411696
- Testing
- dexamethasone intravitreal implant 0.7 mg
- Where
- United States
- Volunteers
- 289 people
- Sponsor
- Allergan
Retinal Vein Occlusion
Extended Follow-up of Patients With Macular Edema Due to Retinal Vein Occlusion
This study evaluates long-term safety in patients with macular edema due to Retinal Vein Occlusion (RVO) originally enrolled in the BRAVO \& CRUISE trials and subsequently followed in the HORIZON extension trial.
- Trial name
- RETAIN (NCT01198327)
- Testing
- ranibizumab, Peripheral Laser
- Where
- 6 sites in United States
- Volunteers
- 66 people
- Sponsor
- Peter A Campochiaro, MD
Macular Edema, Retinal Vein Occlusion
A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion (CRUISE)
This was a Phase III, multicenter, randomized, double-masked, sham injection-controlled study of the efficacy and safety of intravitreal ranibizumab compared with sham injections in patients with macular edema secondary to…
- Trial name
- CRUISE (NCT00485836)
- Testing
- Ranibizumab injection 0.3 mg, Ranibizumab injection 0.5 mg
- Volunteers
- 392 people
- Sponsor
- Genentech, Inc.
Macular Edema, Cystoid, Retinal Vein Occlusion
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study
The SCORE Study will compare the effectiveness and safety of standard care to intravitreal injection(s) of triamcinolone for treating macular edema (swelling of the central part of the retina) associated with central retinal vein…
- Trial name
- SCORE (NCT00105027)
- Testing
- Standard Care, intravitreal triamcinolone injection
- Where
- United States
- Volunteers
- 682 people
- Sponsor
- The Emmes Company, LLC
Branch Retinal Vein Occlusion
Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)
This is a phase III, double-masked, randomized, active-controlled, parallel-group, 52-week study to assess the efficacy and safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) compared to laser treatment in…
- Trial name
- VIBRANT (NCT01521559)
- Testing
- Macular Laser Photocoagulation, Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)
- Where
- 56 sites in United States, Canada and 1 more
- Volunteers
- 183 people
- Sponsor
- Regeneron Pharmaceuticals
Central Retinal Vein Occlusion, Branch Retinal Vein Occlusion
Retrospective Study of the Effectiveness and Safety of Niacin and Steroid Eye Drops for Retinal Vein Occlusions
The aim of this study is to develop a less risky, yet effective and more sustainable treatment for retinal vein occlusions than the current commonly used approach of repeated intravitreal triamcinolone acetonide (Kenalog)…
- Trial name
- NCT00500045
- Testing
- nicotinic acid
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Palo Alto Medical Foundation
Ischemia, Retinal Vein Occlusion
Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2)
The RAVE 2 trial is a phase I, open label, 12-month trial of intravitreal ranibizumab 2.0 mg in patients with ischemic CRVO who have been either previously treated with ranibizumab or treatment naïve.
- Conditions
- Ischemia, Retinal Vein Occlusion, Pathologic Processes, Retinal Diseases
- Trial name
- RAVE2 (NCT01225146)
- Testing
- ranibizumab
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- David M. Brown, M.D.
Macular Edema
A Retrospective Data Collection Study in Patients Receiving Dexamethasone Intravitreal Implant (Ozurdex®) for Macular Oedema Due to Retinal Vein Occlusion (RVO)
This study will use retrospective data to evaluate the efficacy, safety, and re-injection interval of OZURDEX® in the treatment of macular oedema due to Retinal Vein Occlusion (RVO).
- Trial name
- NCT01445626
- Testing
- dexamethasone intravitreal implant 0.7 mg
- Where
- Germany
- Volunteers
- 87 people
- Sponsor
- Allergan
Macular Edema, Retinal Vein Occlusion
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)
This Phase 3 study will evaluate the efficacy, durability, and safety of KSI-301 compared to aflibercept, in participants with macular edema due to treatment-naïve branch (BRVO) or central retinal vein occlusion (CRVO).
- Trial name
- BEACON (NCT04592419)
- Testing
- KSI-301, Aflibercept
- Where
- 141 sites in United States, Czechia and 10 more
- Volunteers
- 568 people
- Sponsor
- Kodiak Sciences Inc
Macular Edema Secondary to Retinal Vein Occlusion
A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion)
Researchers are looking for a better way to treat people who have macular edema secondary to retinal vein occlusion (RVO). In people with RVO, a blood vessel that carries blood away from the retina (vein) becomes blocked.
- Trial name
- QUASAR (NCT05850520)
- Testing
- Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose, Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg, Fluorescein
- Where
- 273 sites in United States, Australia and 25 more
- Volunteers
- 892 people
- Sponsor
- Bayer
Retinal Vein Occlusion, Age Related Macular Degeneration
Efficacy and Safety of Lucentis® (Ranibizumab Intravitreal Injections) in Chilean Patients With Diabetic Macular Edema.
Ranibizumab is a humanized anti-vascular endothelial growth factor (VEGF) monoclonal antibody fragment approved in Chile by the Instituto de Salud Pública for the treatment of diabetic macular edema (DME), retinal vein occlusion…
- Trial name
- NCT02140411
- Testing
- Ranibizumab Intravitreal injections
- Where
- Chile
- Volunteers
- 21 people
- Sponsor
- Novartis Pharmaceuticals
Macular Edema, Retinal Vein Occlusion
A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRAVO)
This was a Phase III, multicenter, randomized, double-masked, sham injection-controlled study of the efficacy and safety of intravitreal ranibizumab compared with sham injections in patients with macular edema secondary to branch…
- Trial name
- BRAVO (NCT00486018)
- Testing
- Ranibizumab injection 0.3 mg, Ranibizumab injection 0.5 mg
- Volunteers
- 397 people
- Sponsor
- Genentech, Inc.
Central Retinal Vein Occlusion With Macular Edema, Branch Retinal Vein Occlusion With Macular Edema
Phase 1 Open-label Study to Evaluate Efficacy and Tolerability of TLC399 in Patients With Macular Edema Due to RVO
To determine whether TLC399 (ProDex) provides an ideal, safe, long-acting, dexamethasone sodium phosphate (DSP) delivery system for the treatment of macular edema due to retinal vein occlusion (RVO).
- Trial name
- NCT02006147
- Testing
- TLC399
- Where
- 6 sites in Taiwan
- Volunteers
- 14 people
- Sponsor
- Taiwan Liposome Company